Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02598349 · ClinicalTrials.gov registry record · Phase 2
Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
A Phase 2 study of Pancreatic Cancer, sponsored by Proton Collaborative Group.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT02598349 is a Phase 2 study of Pancreatic Cancer that is actively recruiting participants, run by Proton Collaborative Group. The registered enrollment target is 60 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT02598349, a Phase 2 study of Pancreatic Cancer, is actively recruiting participants, sponsored by Proton Collaborative Group.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
The prognosis for patients with localized pancreatic adenocarcinoma who are not surgical candidates is poor. Patients characterized as having "borderline resectable" disease treated with preoperative chemo-radiotherapy fair somewhat better - although many of these patients are not converted to resectability. It may be argued that intensification of local and regional therapy might 1.) Increase the share of patients able to undergo curative surgery and 2.) Improve the local disease control interval and extend survival for patients who remain unresectable. Therefore, the purpose of this research study is to determine if an increase in the number of surgical resection pancreatic adenocarcinoma is higher than historical data by using a combined treatment of proton radiation with capecitabine (oral chemotherapy).
Conditions Studied
Interventions
- DRUG Capecitabine
- PROCEDURE Surgical resection
- RADIATION Proton Radiation
Study Locations (4)
Florida
- University of Florida Proton Therapy Institute - Jacksonville
Illinois
- Northwestern Medicine Chicago Proton Center - Warrenville
Michigan
- McLaren Proton Therapy Center - Flint
Virginia
- Inova Schar Cancer Institute - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-04 |
| Est. Completion | 2040-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02598349
The ClinicalTrials.gov registry entry for NCT02598349 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (85% lower). The listed sponsor is Proton Collaborative Group, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which Capecitabine is the first listed.
NCT02598349 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Illinois, Michigan.
Frequently Asked Questions
What is clinical trial NCT02598349 about?
NCT02598349 is a clinical study titled "Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas". The prognosis for patients with localized pancreatic adenocarcinoma who are not surgical candidates is poor. Patients characterized as having "borderline resectable" disease treated with preoperative chemo-radiotherapy fair somewhat better - although many of these patients are not converted to resec...
What is the current status of trial NCT02598349?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2016-04. Estimated completion is 2040-10.
What conditions does trial NCT02598349 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT02598349?
The interventions under investigation include: Capecitabine (DRUG), Surgical resection (PROCEDURE), Proton Radiation (RADIATION).
Who is sponsoring clinical trial NCT02598349?
This trial is sponsored by Proton Collaborative Group, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02598349 being conducted?
This trial has 4 study locations across Florida, Illinois, Michigan, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.